Cyclophosphamide (generic), Cytoxan
Cyclophosphamide (generic), Cytoxan Newswire (Page 3)

Cyclophosphamide (generic), Cytoxan Newswire (Page 3)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 3)

Results 41 - 60 of 242 in Cyclophosphamide (generic), Cytoxan

  1. Kite Pharma Presents Clinical Biomarker Results in Patients Treated...Read the original story w/Photo

    Jun 2, 2015 | GlobeNewswire

    Kite Pharma, Inc., , today announced clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor T-cell therapy in a poster presentation during the 51st Annual Meeting of the American Society of Clinical Oncology , which is taking place in Chicago.

    Comment?

  2. The European Commission (EC) Approves s Akynzeo...Read the original story

    Jun 1, 2015 | BioSpace

    The European Commission Approves Helsinn 's Akynzeo for the Prevention Of Chemotherapy Induced Nausea And Vomiting In The European Union , the European Commission approved Akynzeo for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union. Akynzeo is a new oral fixed dose combination of a highly-selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting .

    Comment?

  3. The European Commission Approves Helsinn's AkynzeoA ...Read the original story

    Jun 2, 2015 | Sys-Con Media

    AkynzeoA is a new oral fixed dose combination of a highly-selective NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting . CINV is one of the most common side effects of chemotherapy.

    Comment?

  4. ASCO15: Aduro Biotech Announces Presentation Of Encouraging Data From ...Read the original story

    May 31, 2015 | BioSpace

    Aduro Biotech, Inc. today announced the presentation of interim safety and efficacy data from an ongoing Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma . Of the 32 evaluable patients, disease control was observed in 94% , including 60% with partial responses and 34% experiencing stable disease following treatment with CRS-207 and chemotherapy.

    Comment?

  5. ASCO 15: Heat Biologics To Present Interim Immune Response Data From...Read the original story

    May 28, 2015 | BioSpace

    Heat Biologics, Inc. , a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that a poster highlighting viagenpumatucel-L in combination with low dose cyclophosphamide in advanced non-small cell lung cancer will be presented at the American Society of Clinical Oncology annual meeting, being held at McCormick Place in Chicago, Illinois, May 29-June 2, 2015. The poster will be presented by Dr. Roger Cohen of the Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, and lead Principal Investigator for the trial.

    Comment?

  6. Pegylated liposomal doxorubicin (Lipo-Dox ) combined with...Read the original story

    May 21, 2015 | BioMed Central

    Pegylated liposomal doxorubicin combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study Division of Hematology-Oncology, Department of Internal Medicine, LinKo Chang Gung Memorial Hospital, 5, Fushing St., Gueishan Township, Taoyuan 333, Taiwan The electronic version of this article is the complete one and can be found online at:

    Comment?

  7. Genmab A/S Release: Ofatumumab And Daratumumab Data To Be Presented...Read the original story

    May 20, 2015 | BioSpace

    Genmab A/S announced today that data on ofatumumab and daratumumab will be presented at the 20th Congress of the European Hematology Association in Vienna, June 11-14. The abstracts have been published at the EHA website at www.ehaweb.org .

    Comment?

  8. 5-HT3 Receptor Antagonist Effects in Cancer Patients With Multiple...Read the original story

    May 15, 2015 | The American Journal of Managed Care

    ABSTRACT Objectives: To examine the impact of palonosetron versus other 5-HT3 receptor antagonists on the incidence of delayed chemotherapy-induced nausea and vomiting in cycle 1 of chemotherapy based on the presence of the following risk factors: age <50 years, female sex, prior CINV, anxiety, no or minimal alcohol use, history of motion sickness, and emetogenicity of chemotherapy. Study Design: Retrospective claims analysis.

    Comment?

  9. Sangamo BioSciences Provides Clinical Update On SB-728-T Program and...Read the original story

    May 13, 2015 | BioSpace

    Sangamo BioSciences Provides Clinical Update On SB-728-T Program and Developments In Other ZFP Therapeutic Programs at American Society of Gene and Cell Therapy Annual Meeting /PRNewswire/ -- Sangamo BioSciences, Inc. announced that clinical and preclinical data from several ZFP TherapeuticA programs and collaborations were presented in the first two days of the 18th Annual Meeting of the American Society of Gene and Cell Therapy . The meeting is being held in "As the largest gene and cell therapy conference in the world, this is a key meeting at which to highlight the power and breadth of therapeutic applications of our ZFP technology," stated , Sangamo's president and CEO.

    Comment?

  10. Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    May 12, 2015 | Seeking Alpha

    Ladies and gentlemen, thank you for standing by, and welcome to the First Quarter Financial Results for Genmab. At this time, all participants are in a listen-only mode.

    Comment?

  11. BRIEF-Genmab Q1 operating income rise, keeps 2015 guidanceRead the original story

    May 12, 2015 | Reuters

    * Says had a cash position of 2,945 million crowns. This represented a net increase of 285 million crowns from beginning of 2015 * Says positive top-line results from phase III complement 2 study of Arzerra plus fludarabine and cyclophosphamide in relapsed CLL * Says revenue was 107 million crowns in first quarter of 2015, compared to 247 million crowns in first quarter of 2014 * Says is maintaining its updated 2015 financial guidance published on march 11, 2015 Source text for Eikon: Further company coverage:

    Comment?

  12. New research could lead to a blood test for common pain syndrome fibromyalgiaRead the original story w/Photo

    May 12, 2015 | PhysOrg Weblog

    Fibromyalgia is common pain syndrome causing widespread muscle and bone pain, as well as fatigue and disturbed sleep. It has no obvious physical cause, is poorly understood and difficult to diagnose, treat and manage.

    Comment?

  13. Transcriptional profiling provides insights into metronomic...Read the original story

    May 7, 2015 | BioMed Central

    Background Cyclophosphamide treatment on a six-day repeating metronomic schedule induces a dramatic, innate immune cell-dependent regression of implanted gliomas. However, little is known about the underlying mechanisms whereby metronomic cyclophosphamide induces innate immune cell mobilization and recruitment, or about the role of DNA damage and cell stress response pathways in eliciting the immune responses linked to tumor regression.

    Comment?

  14. Acacia Pharma reports positive results from APD403 Phase 2 study in CINVRead the original story w/Photo

    May 6, 2015 | Medical News

    Acacia Pharma Ltd , a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting . CINV occurs in approximately 70% of all cancer patients receiving chemotherapy and in 90% of those receiving highly emetogenic chemotherapy .

    Comment?

  15. Acacia Pharma Announces Positive Results From Phase 2 Study With...Read the original story

    May 6, 2015 | Sys-Con Media

    Acacia Pharma Ltd , a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting . CINV occurs in approximately 70% of all cancer patients receiving chemotherapy and in 90% of those receiving highly emetogenic chemotherapy .

    Comment?

  16. LCC to host Relay for Life Survivor's Banquet TuesdayRead the original story w/Photo

    May 4, 2015 | Kinston Free Press

    Tonight, Lenoir Community College will host the Relay for Life Survivor Banquet. Cancer survivors will gather for fellowship, a dinner with a short program and, most importantly, a celebration.

    Comment?

  17. High doses of triptorelin needed for ovarian suppression in SLERead the original story w/Photo

    May 4, 2015 | PhysOrg Weblog

    For female patients with childhood-onset systemic lupus erythematosus who require treatment with cyclophosphamide, sustained complete ovarian suppression is achieved in 90 percent of the patients with triptorelin at a weight-adjusted dose of 120 A g/kg body weight, according to a study published in the May issue of Arthritis & Rheumatology . Hermine I. Brunner, M.D., from the Cincinnati Children's Hospital Medical Center, and colleagues sought to determine the dose and duration of triptorelin that is sufficient to maintain complete ovarian suppression in patients with childhood-onset SLE who require cyclophosphamide .

    Comment?

  18. The spinal cord in springtimeRead the original story

    May 3, 2015 | T. Scott

    Email alert Wednesday morning that there was a message waiting for me in the patient portal. Nervous as I logged in, anticipating the results of the previous afternoon's scan.

    Comment?

  19. Plasmablastic lymphoma of the oral cavity with breast recurrence: a case reportRead the original story

    Apr 30, 2015 | BioMed Central

    Background Plasmablastic lymphoma is an aggressive variant of diffuse large B cell lymphoma, mostly found in the oral cavity and associated with human immunodeficiency virus. There are no clear guidelines for its treatment.

    Comment?

  20. Sangamo BioSciences And Collaborators To Present Data On ZFP...Read the original story

    Apr 29, 2015 | Information Technology

    Twelve oral and six poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs including HIV/AIDS, hemoglobinopathies, lysosomal storage disorders, and other monogenic diseases, cancer immunotherapy and advancements in technology including delivery. Additionally, members of Sangamo's management team and Company scientists will participate in the C-Suite Executive Panel and two Education Sessions.

    Comment?